Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingfeng Ganke
- Development stage
- Phase 3
- Lead developer
- West China Hospital of Sichuan University
- Administration
- Oral
01
Overview
Qingfeng Ganke is a Traditional Chinese Medicine (TCM) formulation developed as granules for the treatment of postinfectious cough (PIC), specifically targeting the Wind-evil Loving Lung syndrome (风邪伏肺证). Developed by West China Hospital of Sichuan University, it is designed to alleviate persistent coughing that follows a respiratory tract infection. The formulation typically consists of multiple herbal ingredients aimed at clearing wind, ventilating the lungs, and relieving cough. It has been evaluated in Phase II clinical trials to assess its efficacy and safety compared to placebo in patients with postinfectious cough.
- Brand names
- Qingfeng Ganke Granules
- Other names
- Qingfeng Ganke Granules
Beyond the preview
Go deeper on Qingfeng Ganke.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Qingfeng Ganke.